Search Results
Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
HER2-low breast cancer: the ESMO Expert Consensus Statements
Overview of the management of HER2-low breast cancer patients
Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer
Questions remaining in the field of HER2-low breast cancer
HER2-low expression in breast cancer
Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer
The Latest Treatments for Uterine Cancer and What’s in the Pipeline
Remaining questions regarding HER2-low breast cancer
New Targeted Therapy Options for ER Positive, HER2 Negative, Advanced Breast Cancer
Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer
